Labcorp Partners on National Trial to Boost Genetic Testing in Colorectal Cancer
Event summary
- Labcorp collaborates with the Alliance for Clinical Trials in Oncology on a national, multicenter trial for colorectal cancer patients.
- Trial aims to evaluate proactive healthcare provider outreach to increase germline genetic testing among at-risk family members.
- Labcorp's Invitae testing will be the exclusive genetic testing provider for the trial.
- Study sponsored by the National Cancer Institute (NCI) and includes participation from academic medical centers and NCI-designated cancer centers nationwide.
The big picture
This collaboration underscores Labcorp's strategic push into genetics-based oncology solutions, aligning with broader industry trends toward personalized medicine. The trial's focus on cascade testing addresses a critical gap in preventive care for hereditary cancer syndromes, potentially reshaping how genetic risk is communicated to at-risk relatives nationwide.
What we're watching
- Execution Risk
- Whether Labcorp can effectively scale its Invitae testing across the diverse network of participating sites.
- Regulatory Impact
- How the trial's findings may influence future guidelines for genetic testing in colorectal cancer care.
- Market Positioning
- The pace at which Labcorp can leverage this collaboration to strengthen its leadership in oncology diagnostics.
Related topics